159 related articles for article (PubMed ID: 7236992)
41. Adenosine-5'-O-(2-thiodiphosphate) is a potent agonist at P2 purinoceptors mediating insulin secretion from perfused rat pancreas.
Bertrand G; Chapal J; Puech R; Loubatières-Mariani MM
Br J Pharmacol; 1991 Mar; 102(3):627-30. PubMed ID: 1364829
[TBL] [Abstract][Full Text] [Related]
42. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.
Matthews JS; Jones RL
Br J Pharmacol; 1993 Feb; 108(2):363-9. PubMed ID: 8448586
[TBL] [Abstract][Full Text] [Related]
43. Specific but noncompetitive inhibition by 2-alkylthio analogues of adenosine 5'-monophosphate and adenosine 5'-triphosphate of human platelet aggregation induced by adenosine 5'-diphosphate.
Cusack NJ; Hourani SM
Br J Pharmacol; 1982 Feb; 75(2):397-400. PubMed ID: 7186826
[TBL] [Abstract][Full Text] [Related]
44. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
45. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
[TBL] [Abstract][Full Text] [Related]
46. Two mechanisms for inhibition of ADP-induced platelet shape change by 5'-p-fluorosulfonylbenzoyladenosine. Conversion to adenosine, and covalent modification at an ADP binding site distinct from that which inhibits adenylate cyclase.
Mills DC; Figures WR; Scearce LM; Stewart GJ; Colman RF; Colman RW
J Biol Chem; 1985 Jul; 260(13):8078-83. PubMed ID: 2989276
[TBL] [Abstract][Full Text] [Related]
47. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Weber AA; Reimann S; Schrör K
Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
[TBL] [Abstract][Full Text] [Related]
48. On the interrelationship of prostaglandin endoperoxide G2 and cyclic nucleotides in platelet function.
Claesson HE; Malmsten C
Eur J Biochem; 1977 Jun; 76(1):277-84. PubMed ID: 195812
[TBL] [Abstract][Full Text] [Related]
49. Partial agonism of prostaglandin H2 analogs and 11-deoxy-prostaglandin F2 alpha to thromboxane-sensitive preparations.
Jones RL; Wilson NH
Adv Prostaglandin Thromboxane Res; 1980; 6():467-75. PubMed ID: 7386280
[No Abstract] [Full Text] [Related]
50. Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium.
Pollock WK; Armstrong RA; Brydon LJ; Jones RL; MacIntyre DE
Biochem J; 1984 May; 219(3):833-42. PubMed ID: 6234886
[TBL] [Abstract][Full Text] [Related]
51. Inhibition by a stable analogue of adenosine triphosphate of platelet aggregation by adenosine diphosphate.
Born GV; Foulks JG
Br J Pharmacol; 1977 Sep; 61(1):87-9. PubMed ID: 912211
[TBL] [Abstract][Full Text] [Related]
52. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.
MacIntyre DE; Handin RI; Rosenberg R; Salzman EW
Thromb Res; 1981 Apr 1-15; 22(1-2):167-75. PubMed ID: 6270842
[No Abstract] [Full Text] [Related]
53. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors.
Humphries RG; Tomlinson W; Ingall AH; Cage PA; Leff P
Br J Pharmacol; 1994 Nov; 113(3):1057-63. PubMed ID: 7858849
[TBL] [Abstract][Full Text] [Related]
54. Characterization of the distinct mechanism of agonist-induced canine platelet activation.
Chaudhary PK; Kim S
J Vet Sci; 2019 Jan; 20(1):10-15. PubMed ID: 30541187
[TBL] [Abstract][Full Text] [Related]
55. Identification of a receptor for ADP on blood platelets by photoaffinity labelling.
Cristalli G; Mills DC
Biochem J; 1993 May; 291 ( Pt 3)(Pt 3):875-81. PubMed ID: 8387782
[TBL] [Abstract][Full Text] [Related]
56. Removal of extraplatelet Na+ eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombin.
Connolly TM; Limbird LE
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5320-4. PubMed ID: 6577431
[TBL] [Abstract][Full Text] [Related]
57. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
58. AH6809, a prostaglandin DP-receptor blocking drug on human platelets.
Keery RJ; Lumley P
Br J Pharmacol; 1988 Jul; 94(3):745-54. PubMed ID: 2460179
[TBL] [Abstract][Full Text] [Related]
59. Platelet prostaglandin production and its implications.
Smith JB; Ingerman CM; Silver MJ
Adv Prostaglandin Thromboxane Res; 1976; 2():747-53. PubMed ID: 983875
[TBL] [Abstract][Full Text] [Related]
60. Responses of rabbit platelets to adrenaline induced by other agonists.
Hallam TJ; Scrutton MC; Wallis RB
Thromb Res; 1981 Feb 15-Mar 1; 21(4-5):413-24. PubMed ID: 7268693
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
